OBJECTIVE: To compare presentation of Alzheimer disease (AD) at the time of initial evaluation at a university specialty clinic across three ethnoracial groups in order to understand similarities and differences in the demographic, clinical, cognitive, psychiatric, and biologic features. DESIGN: Cross-sectional study. PARTICIPANTS: A total of 1,341 self-identified African American, Latino (primarily of Caribbean origin), and white non-Hispanic ("WNH") subjects were recruited from primary care sites or by referral by primary care physicians. MEASUREMENTS: Demographic variables and age of onset of AD, as well as cognitive, functional, and mood impairments at the time of initial presentation and frequencies of apolipoprotein E genotypes, were compared across groups. RESULTS: Differences among ethnoracial groups were found for nearly all variables of interest. In particular, the largely immigrant Puerto Rican Latino group had an earlier age of onset of AD, more cognitive impairment, and greater severity of cognitive impairment at the time of initial evaluation in the setting of low average education and socioeconomic status. There was more depression in the Latinos compared with African Americans and WNHs. Greater severity of symptoms was not accounted for by a difference in lag time between onset of symptoms and initial evaluation. The apolipoprotein E-4 genotype was not associated with AD in the Latino cohort. CONCLUSIONS: Minority groups in Philadelphia, especially Latinos, exhibit a more severe profile of AD at the time of presentation than WNHs. Important potential confounds need to be considered and future research comparing immigrant and nonimmigrant Latino groups will be necessary to elucidate the highly significant differences reported.
OBJECTIVE: To compare presentation of Alzheimer disease (AD) at the time of initial evaluation at a university specialty clinic across three ethnoracial groups in order to understand similarities and differences in the demographic, clinical, cognitive, psychiatric, and biologic features. DESIGN: Cross-sectional study. PARTICIPANTS: A total of 1,341 self-identified African American, Latino (primarily of Caribbean origin), and white non-Hispanic ("WNH") subjects were recruited from primary care sites or by referral by primary care physicians. MEASUREMENTS: Demographic variables and age of onset of AD, as well as cognitive, functional, and mood impairments at the time of initial presentation and frequencies of apolipoprotein E genotypes, were compared across groups. RESULTS: Differences among ethnoracial groups were found for nearly all variables of interest. In particular, the largely immigrant Puerto Rican Latino group had an earlier age of onset of AD, more cognitive impairment, and greater severity of cognitive impairment at the time of initial evaluation in the setting of low average education and socioeconomic status. There was more depression in the Latinos compared with African Americans and WNHs. Greater severity of symptoms was not accounted for by a difference in lag time between onset of symptoms and initial evaluation. The apolipoprotein E-4 genotype was not associated with AD in the Latino cohort. CONCLUSIONS: Minority groups in Philadelphia, especially Latinos, exhibit a more severe profile of AD at the time of presentation than WNHs. Important potential confounds need to be considered and future research comparing immigrant and nonimmigrant Latino groups will be necessary to elucidate the highly significant differences reported.
Authors: M X Tang; P Cross; H Andrews; D M Jacobs; S Small; K Bell; C Merchant; R Lantigua; R Costa; Y Stern; R Mayeux Journal: Neurology Date: 2001-01-09 Impact factor: 9.910
Authors: D A Bennett; R S Wilson; J A Schneider; D A Evans; C F Mendes de Leon; S E Arnold; L L Barnes; J L Bienias Journal: Neurology Date: 2003-06-24 Impact factor: 9.910
Authors: Denis A Evans; David A Bennett; Robert S Wilson; Julia L Bienias; Martha Clare Morris; Paul A Scherr; Liesi E Hebert; Neelum Aggarwal; Laurel A Beckett; Rajiv Joglekar; Elizabeth Berry-Kravis; Julie Schneider Journal: Arch Neurol Date: 2003-02
Authors: Jasenka Demirovic; Ronald Prineas; David Loewenstein; Judy Bean; Ranjan Duara; Steven Sevush; Jose Szapocznik Journal: Ann Epidemiol Date: 2003-07 Impact factor: 3.797
Authors: Irving E Vega; Laura Y Cabrera; Cassandra M Wygant; Daniel Velez-Ortiz; Scott E Counts Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Dawnté R Early; Keith F Widaman; Danielle Harvey; Laurel Beckett; Lovingly Quitania Park; Sarah Tomaszewski Farias; Bruce R Reed; Charles Decarli; Dan Mungas Journal: Psychol Aging Date: 2013-02-25
Authors: Jamie L Hamilton; Adam M Brickman; Rosalyn Lang; Goldie S Byrd; Jonathan L Haines; Margaret A Pericak-Vance; Jennifer J Manly Journal: J Int Neuropsychol Soc Date: 2014-05-19 Impact factor: 2.892
Authors: John M Ringman; Michael C Sachs; Yan Zhou; Sarah E Monsell; Jeffrey L Saver; Harry V Vinters Journal: JAMA Neurol Date: 2014-07-01 Impact factor: 18.302
Authors: Shanna L Burke; Miriam J Rodriguez; Warren Barker; Maria T Greig-Custo; Monica Rosselli; David A Loewenstein; Ranjan Duara Journal: J Int Neuropsychol Soc Date: 2017-09-18 Impact factor: 2.892
Authors: Halima Amjad; David L Roth; Orla C Sheehan; Constantine G Lyketsos; Jennifer L Wolff; Quincy M Samus Journal: J Gen Intern Med Date: 2018-03-05 Impact factor: 5.128
Authors: Guilherme M Balbim; Ashley M Maldonado; Amy Early; Lesley Steinman; Kristin Harkins; David X Marquez Journal: Hisp Health Care Int Date: 2020-03-03
Authors: John Q Trojanowski; Steven E Arnold; Jason H Karlawish; Mary Naylor; Kurt R Brunden; Virginia M Y Lee Journal: Alzheimers Dement Date: 2012-11 Impact factor: 21.566